0000899243-23-001803.txt : 20230113 0000899243-23-001803.hdr.sgml : 20230113 20230113183336 ACCESSION NUMBER: 0000899243-23-001803 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230113 FILED AS OF DATE: 20230113 DATE AS OF CHANGE: 20230113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gould Robert J CENTRAL INDEX KEY: 0001577034 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38978 FILM NUMBER: 23529876 MAIL ADDRESS: STREET 1: C/O EPIZYME, INC. STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc. CENTRAL INDEX KEY: 0001680581 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474839948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-651-8851 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-13 0 0001680581 Fulcrum Therapeutics, Inc. FULC 0001577034 Gould Robert J C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 1 1 0 0 Interim President & CEO Common Stock 2023-01-13 4 S 0 6766 15.00 D 499864 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022. /s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould 2023-01-13